For European tech start-ups, 2006 was the year that the traffic lights for money switched from red to yellow. Yet to be seen is whether they finally go green next year.
Pharminox Ltd, a private oncology R&D company backed by IP Group, is to carry out joint research into novel small molecule chemotherapeutics with Schering-Plough.
Galapagos NV is bolstering its ability to select drug targets and compounds by acquiring Inpharmatica Ltd in an all-share transaction that values the UK bioinformatics company at €12.5 million.
Three reports, two commissioned by possible next premier Gordon Brown and one inspired by him provide a glimpse of the future shape of UK innovation policy.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.